On this page of StockholderLetter.com we present the latest annual shareholder letter from CROSS COUNTRY HEALTHCARE INC — ticker symbol CCRN. Reading current and past CCRN letters to shareholders can bring important insights into the investment thesis.

 •  3/30/2026 Letter Continued (Full PDF)
 •  4/3/2023 CCRN Stockholder Letter
 •  4/1/2024 CCRN Stockholder Letter
 •  10/27/2025 CCRN Stockholder Letter
 •  More "Diagnostics" Category Stockholder Letters
 •  CCRN Benford's Law Stock Score = 83

CCRN Shareholder/Stockholder Letter Transcript:

2025
L E A D E R S H I P.
I N N O V AT I O N .
ACCOU N TA B IL I T Y.
2 0 2 5 A N N UA L R E P ORT


Dear Shareholders,
As we enter 2026, I am honored to once again serve as Chief Executive Officer of Cross
Country Healthcare. This company has been central to my professional life for four decades,
and I return to this role with a clear mandate: restore momentum, sharpen execution, and
position our organization to grow faster than the market once again.
2025 was a year of disruption, not a year of diminished relevance. The pending merger
created uncertainty in the marketplace that impacted our ability to win new business and
slowed our commercial momentum. While the transaction was not consummated, the
overhang affected growth during the year. What did not change, however, was the strength
of our client relationships, our reputation for clinical excellence, or the resilience of our
balance sheet.
Cross Country Healthcare remains a trusted partner to leading health systems across
the country. For more than forty years, we have delivered highly quali   ed healthcare
professionals who meet the most demanding clinical standards. In an industry where
reliability, quality, and patient outcomes matter deeply, that trust remains one of our most
valuable assets.
We enter 2026 with no debt, a strong capital position, and the    nancial    exibility to invest
strategically in growth. Our capital allocation priorities are disciplined and clear: invest
in technology, expand share within large health systems, enhance operational execution
across our divisions, and deploy capital where we can generate durable, long-term returns.
A central pillar of our strategy is Intellify, our AI-enabled technology platform. Intellify is
transforming how we solve complex workforce challenges across the continuum of care.
By integrating data, automation, and intelligent matching capabilities, we are improving
   ll rates, accelerating speed to placement, and delivering greater transparency to clients.
Technology is no longer a support function within our business; it is a competitive advantage.
Our focus in 2026 is execution. We are aligning our teams around disciplined commercial
expansion, operational rigor, and market share capture. We are not rebuilding this company.
We are refocusing it   leveraging a strong foundation to drive renewed growth.
As we execute our strategic priorities, we expect to return to revenue and earnings growth
by the end of 2026. Importantly, our strategy does not depend on market recovery alone.
We are focused on outperforming the market through client expansion, differentiated
technology, and consistent operational excellence.
Cross Country Healthcare has successfully navigated multiple industry cycles over the past
four decades. We enter this next chapter with clarity of strategy,    nancial strength, and
renewed leadership focus. I am con   dent in our ability to build on our legacy and create
meaningful, long-term value for our shareholders.
Thank you for your continued trust and support.
Sincerely,
Kevin C. Clark
Co-Founder, Chairman of the Board of Directors, and
Chief Executive Officer
Cross Country Healthcare, Inc.

Form 10-K


+0B78=6C>=           
666666666666666666


 "")   & $#&( $)&') "( (# '  ( #"   #&    3  #  (   '  )& (  '  ,   "     (
 >A C74  8B20; -40A  =343  424<14A    

>A

(& "' ( #" & $#&( $)&') "( (# '  ( #"   #&    3  #  (   '  )& (  '  ,   "  
 >A C74 CA0=B8C8>= ?4A8>3 5A>< 6666666666 C> 6666666666
 ><<8BB8>= 58;4 =D<14A   

 A>BB  >D=CAH  40;C720A4   =2
  N79J D7C; E< H;=?IJH7DJ 7I IF;9?7HJ;H
 4;0F0A4
 -J7J; EH EJ>;H @KH?I:?9J?ED E< ?D9EHFEH7J?ED EH EH=7D?P7J?ED

 # , -   CFBEO;H #:;DJ?=6A4BB  E4=D4  'D8C4   
 >20 &0C>=   ;>A830     
  ::H;II E< FH?D9?F7B ;N;9KJ?L; E<ED; DKC8;H  ?D9BK:?D= 7H;7 9E:;            
'42DA8C84B A468BC4A43 ?DABD0=C C> '42C8>=   1  >5 C74  2C 
(8C;4 >5 4027 2;0BB
 ECCED -JE9A  F7H L7BK;         F;H I>7H;
(A038=6 BH<1>;

"0<4 >5 4027 4G270=64 >= F7827 A468BC4A43
.>; (7I:7G -JE9A '7HA;J && 
-;9KH?J?;I H;=?IJ;H;: FKHIK7DJ JE -;9J?ED    =  E< J>; 79J  (ED;

3/30/2026 Letter Continued (Full PDF)

 

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.